Dynacirc (Isradipine) is recommended for the treatment of essential hypertension.
Dynacirc (Isradipine) can be administered with or without food. The recommended dosage is 2.5 mg twice a day (i.e. about every 12 hours). Treatment for 3-4 weeks is required for the maximum effect to develop. If blood pressure is not adequately controlled after this period patients may require a dosage of 5 mg twice a day, or if more appropriate, the addition of a low dose of another anti-hypertensive agent i.e. thiazide diuretic or beta-blocker. Exceptionally some patients may require up to 10mg twice a day. Dynacirc (Isradipine) can also be added to an ongoing regimen of other anti-hypertensive agents.
Clinical studies indicate that Dynacirc (Isradipine) is well tolerated with an overall incidence of adverse events similar to that of placebo when used in doses up to 2.5 mg twice a day. Generally side effects are mild, dose dependent and tend to disappear or decrease in intensity as treatment is continued. Discontinuation of therapy is generally not required. Those side effects mentioned most often are related to the vasodilating properties of Dynacirc (Isradipine): headache, flushing, dizziness, tachycardia and palpitation, and localised peripheral oedema of non-cardiac origin; hypotension is uncommon and there have been no reports of orthostatic hypotension.
Non-specific side effects are rare and include: weight gain, fatigue, abdominal discomfort, and skin rash.
Elevations of serum transaminases have been observed on very rare occasions; these changes were reversible both spontaneously and on following Dynacirc (Isradipine) withdrawal.
As with other dihydropyridines, aggravation of underlying angina has been reported in a small number of individuals especially after starting treatment. This is more likely to happen in patients with symptomatic ischaemic heart disease. Dynacirc (Isradipine) should be discontinued under medical supervision in patients who develop unstable angina.